Adage Capital Partners Gp, L.L.C. Avidity Biosciences, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 1,527,000 shares of RNA stock, worth $67.5 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
1,527,000
Previous 2,145,881
28.84%
Holding current value
$67.5 Million
Previous $63.3 Million
31.54%
% of portfolio
0.08%
Previous 0.12%
Shares
11 transactions
Others Institutions Holding RNA
# of Institutions
232Shares Held
119MCall Options Held
340KPut Options Held
145K-
Price T Rowe Associates Inc Baltimore, MD10.8MShares$478 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X010.8MShares$476 Million0.16% of portfolio
-
Rtw Investments, LP New York, NY9.62MShares$425 Million4.2% of portfolio
-
Wellington Management Group LLP Boston, MA9.25MShares$409 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.25MShares$409 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.3B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...